Skip to content
Search

Latest Stories

London Stock Exchange’s pride in being HDFC bond ‘partner of choice’

One of the most senior figures in the City, Nikhil Rathi, welcomed the launch of HDFC’s masala bond.

Rathi, who is of Indian origin but born in the UK, is the CEO of the London Stock Exchange and also director of international development at the London Stock Exchange Group.


“It’s a fun job,” he told Eastern Eye, adding, “I am very proud of my heritage, very proud I am in this position to support the investment into India through the City of London.”

Alongside him at the event was another senior Indian-origin figure, Ramesh Chhabra, head of media relations at the London Stock Exchange. Known to friends as “Mesh”, he was until last year a special adviser to former chancellor George Osborne.

The London Stock Exchange dates back to 1801 and has the motto, Dictum Meum Pactum, which is Latin for, “Our word is our bond”.

“It’s the most international exchange in the world, the home for international investors, international issuers and today is a landmark event for Indian finance,” Rathi said, speaking immediately after the launch. “And we are very proud that London has been chosen as the partner of choice for the first corporate masala bond anywhere in the world, with HDFC being the pioneer in that market.”

“I believe there is a unique combination here of the India-UK financial partnership, with the deepest global financial centre here in London, the fastest=growing economy in the G20 in India and through the exchange I am very proud that we are able to bring that together,” he went on.

Asked whether the launch would strengthen UK-India relations, Rathi responded: “Absolutely. Prime minister Modi, in November last year, announced London as a masala bond centre – and that is very important because it indicates trust in the regulatory environment in London and trust by investors in London to support sustainable infrastructure financing in India – one of the most exciting and fastest-growing economies in the world.”

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less